Shenlian Bio announced that the number of strategic allotment shares in circulation is 2.5 million shares, with a sales limit of 24 months. The company confirms that the number of shares in circulation is the total number of strategic allotment shares during the restricted period; the listing date of the restricted shares is October 28, 2021.
According to Shenlian Biological 2021, the company's main income was 153 million yuan, down 1.03% from the same period last year; the net profit was 44.421 million yuan, down 26.88% from the same period last year; and the non-net profit was 38.5163 million yuan, down 22.87% from the same period last year. In the second quarter of 2021, the company's main income in a single quarter was 70.1737 million yuan, up 24.93% from the same period last year; and net profit in a single quarter was 16.0373 million yuan, up 17.73% from the same period last year. The non-net profit in a single quarter was 13.4621 million yuan, up 50.64% from the same period last year; the debt ratio was 7.81%, the investment income was 5.4723 million yuan, the financial expenses were-946200 yuan, and the gross profit margin was 81.7%.
The stock has no agency rating in the last 90 days. In the past three months, the net inflow of financing was 3.7267 million, and the financing balance increased; the net outflow of securities loans was 9.8704 million, and the balance of securities loans decreased. According to the Securities Star valuation analysis tool, Shenlian Biological (688098) good company has a rating of 3 stars, a good price rating of 2.5 stars, and a comprehensive valuation rating of 2.5 stars.
The chairman of the company is Nie Dongsheng. Mr. Nie Dongsheng: born in March 1960, Chinese nationality, no permanent right of abode abroad, bachelor's degree, researcher, from July 1982 to May 1987, served as a member of the veterinary department of Henan Animal Husbandry Bureau; from May 1987 to October 1991, he served as head of the epidemic Prevention Section of Henan Veterinary Prevention and Control Station; from October 1991 to October 2001, he served as Deputy Director of Henan Animal Quarantine Station; and from October 2001 to March 2011, he served as Director of Henan Animal Husbandry and Veterinary Magazine. Chairman of Henan Hongzhan Investment Co., Ltd., from December 2006 to September 2017; Board of Directors of Tiankang Biological Co., Ltd., from February 2009 to August 2009; Director of the Company from July 2003 to September 2006; General Manager of the Company from September 2018 to December 2019; Executive Director of Shanghai Yipu Business Consulting Co., Ltd. Since January 2017; Chairman of the Company since September 2006 He has been the director of the company's R & D center since December 2011.
This article is compiled by the Securities Star data Center according to the public data and does not constitute investment opinions or suggestions. If there are any questions in the article, please contact us.